Effects of pioglitazone on visceral fat metabolic activity in patients with type 2 diabetes mellitus or impaired glucose tolerance

VernacularTitle:吡格列酮对2型糖尿病或糖耐量减低患者内脏脂肪代谢活性影响的观察
Author: Yajun LIU ; Jianhong HOU
Publication Type:Journal Article
Keywords: Pioglitazone; Glimepiride; Diabetes mellitus,type 2; Impaired glucose tolerance (IGT ); Visceral fat
From: Chinese Journal of Diabetes 2015;(2):127-130
CountryChina
Language:Chinese
Abstract: Objective To study the effects of pioglitazone on visceral fat tissue metabolic activity in patients with type 2 diabetes mellitus or impaired glucose tolerance by using 18 fluoro deoxy glucose (FDG)‐positron emission tomography (PET)andcomputed tomography (CT)imaging. Methods FDG‐PET and CT imaging were performed in 62 patients with type 2 diabetes mellitus (T2DM ) or impaired glucose tolerance (IGT ). Lipid and glycemic profiles and inflammatory markers were detected in all patients. These patients randomly received treatments with either pioglitazone or glimepiride for 16 weeks.Results After 16 weeks ,pioglitazone‐treated group versus glimepiride‐treated group showed a significantly decreased visceral fat area[(109.1 ± 45.0) vs(122.5 ± 52.0 )cm2 ] and a significantly decreased visceral fat metabolic activity[(0.47 ± 0.11)vs(0.55 ± 0.11)](P<0.05). Conclusion Our study indicates that pioglitazone decreases the visceral fat volume and its metabolic activity in patients with T 2DM or IGT.